Setback for Novartis in preventing heart disease - but hope in another area
The pharmaceutical company Novartis needs a replacement for its current top-selling product Entresto. However, this could come from a different therapeutic area than cardiology.
Novartis' shares fell 3.2% to 125.46 francs on Monday after the company's experimental cardiovascular drug Pelacarsen failed to outperform a placebo in a late-stage study. The setback comes as Novartis faces declining sales of its top-selling heart failure medication Entresto, which generated $7.7 billion in revenue last year but is no longer patent-protected.
Meanwhile, Novartis' multiple sclerosis treatment Remibrutinib, also in the final stage of development, has shown promising results and could bring in $3-5 billion annually. Analysts view the Pelacarsen failure as manageable, and some see more potential in rival Roche's shares.
Written by urgent.news from NZZ Wirtschaft's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- Pharmabranche: Erneuter Rückschlag für Novartis – Aktie gibt nach handelsblatt.com
